Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum
March 11, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
March 02, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
February 15, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 11, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 08, 2021 07:00 ET
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021
October 20, 2021 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million
October 18, 2021 07:00 ET
|
Axsome Therapeutics, Inc.
$100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing...
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
September 16, 2021 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine
September 14, 2021 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder
August 23, 2021 06:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...